Menu
Recruiting NCT03146910

Swiss Primary Biliary Cholangitis Cohort Study

Observational PBC Primary Biliary Cholangitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: PBC, Primary Biliary Cholangitis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Switzerland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Research project in which biological material is sampled and health-related medical data is collected. In addition, already existing health-related medical data are used for further research. Coded data are used.

Detailed description

Enrolment visit and one follow-up visit at least once a year are planned.

Whole blood is collected for biobanking once a year. Optionally, if available and collected during normal clinical procedures, liver fragments are obtained.

To collect high quality prospective data on a rare disease in order to elucidate epidemiology, natural history, response to treatment and outcome. In addition, the biobank allows addressing specific scientific issues on a variety of open questions. The cohort will provide a platform for carrying out scientific research projects on PBC. In addition, the cohort will allow collaboration with reference networks on PBC abroad.

Primary outcome measures

  • Disease course [Time frame: 3 years]
  • Disease features [Time frame: 3 years]
  • Response to treatment [Time frame: 3 years]
  • Overall survival [Time frame: 3 years]
  • Transplantation-free survival rate [Time frame: 3 years]

Eligibility criteria

Inclusion criteria

  • diagnose of Primary biliary cholangitis (according to EASL Clinical Practice Guidelines: management of cholestatic liver diseases).
  • Subjects with isolated anti-mitochondrial antibodies and/or isolated PBC-specific anti-nuclear antibodies are also included
  • Patients/subjects aged at least 18 years and living in Switzerland are included

Exclusion criteria

  • N/A

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Switzerland · 13 centers
  • Fondazione Epatocentro Ticino — Lugano
  • Gastroenterologie und Hepatologie, Clarunis - Universitäres Bauchzentrum Basel — Basel
  • Inselspital — Bern
  • Spital Bülach — Bülach
  • Kantonsspital Graubünden — Chur
  • Hôpitaux Universitaires de Genève, Service de Gastroentérologie & Hépatologie, Département — Geneva
  • CHUV: Centre hospitalier universitaire vaudois — Lausanne
  • Kantonsspital Baselland — Liestal
  • … and 5 more centers

Identifiers

NCT: NCT03146910 · SASL39 - Swiss PBC Cohort

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗